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Effective use of antiretroviral therapy (ART), has greatly upgraded the quality of life and 
survival of individuals suffering from HIV/AIDS. However, the incidence rate of 
hypertension is reported growing up. The overall aim was to find out the prevalence of 
hypertension and its association with HIV related factors in HIV patients on ART, in 
Bagamoyo district Tanzania. The design was a cross-sectional study of HIV patients on ART 
visiting care and treatment clinics. Hypertension was defined as systolic blood pressure ≥ 140 
mmHg, diastolic blood pressure ≥ 90 mmHg or being on medications for hypertension. 
Logistic regression was applied during the analysis. The study investigated 328 HIV patients 
on ART, 64.6% were female, and 92.68% on non-protease inhibitors medication and 14% 
had a prior history of TB in the past 5 years. The overall prevalence of hypertension was 
29.3% and it was significantly and positively associated with increasing age (years): 40-59, 
3.40 (1.80-6.41) 0.001, ≥ 60, 9.25 (3.96-21.60) 0.001, obesity 3.63 (1.60-8.26) 0.002, non-
protease inhibitors 4.31 (1.16-16.03) 0.029 and tenofovir 4.27 (1.15-15.96) 0.031. Both of the 
duration since HIV diagnosed, recent CD4+cell count and history of TB in the past 5 years 
were not statistically significant associated with increased odds of having hypertension. In 
conclusion the prevalence of hypertension in HIV patients on ART was 29.3% and it was 
significantly and positively associated with increasing age, obesity, and non-protease 
inhibitors. Regular monitoring of blood pressure, anthropometrics, and ART drug toxicity are 
crucial among HIV patients. 
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1.1 Background of the problem 
Effective use of antiretroviral therapy (ART), has greatly upgraded the quality of life and 
survival of individuals suffering from HIV/AIDS (Chastain, Henderson & Stover, 2015).  
However, the incidence rate and mortality from cardiovascular risk factors including 
hypertension are reported to growing up (Xu, Chen & Wang, 2017). For example, in a recent 
meta-analysis study prevalence of hypertension was 34.7% among HIV patients on ART 
compared to 12.7% in ART naïve individuals (Xu et al., 2017). In Tanzania, the prevalence 
of hypertension among HIV patients using antiretroviral therapy has been reported to be 
28.3%  (Peck et al., 2014).  This was higher than the prevalence of  5.3% and 16.3%  in HIV 
ART-naïve and  HIV negative individuals respectively (Peck et al., 2014). 
Hypertension (the greatest risk factor of mortality) is a growing health challenge in 
individuals living with HIV/AIDs (Nduka, Stranges, Sarki, Kimani & Uthman, 2016; 
Gakidou et al., 2017). However, the contributions of HIV related factors to hypertension have 
not been extensively investigated in Tanzania. Besides the traditional risk factors, 
hypertension in HIV patients can be attributed to, inflammations, ART toxicity, and immune 
response (Madhur et al., 2016). For instance, tenofovir an ART belongs to non-protease 
inhibitors class has been reported to contribute to hypertension due to its ability to cause renal 
failure and therefore secondary hypertension (Ojeh et al., 2018). Also, higher CD+ cell count 
(following immune reconstitution after initiation of ART) has been reported to associate with 
elevated blood pressure in adults HIV infected individuals (Peck et al., 2014). However, a 
separate study has indicated a lack of association between CD4+cell count and hypertension 
(Medina-Torne et al., 2012). 
Traditional risks include risks such as increasing age, sex, and increasing body mass index 
(Riaz et al., 2016). However, it’s unknown if traditional risk factors may interact with HIV 
related factors to increase the risk of hypertension. Therefore, the cross-sectional study was 
undertaken to investigate the prevalence of hypertension and its association with HIV related 




1.2 Statement of the problem 
Hypertension is the relevant  public health problem including in the individuals suffering 
from HIV/AIDS (Medina-Torne et al., 2012). Effective use of antiretroviral therapy (ART), 
has greatly upgraded the quality of life and survival of individuals living with HIV/AIDS 
(Chastain et al., 2015). However, the incidence rates from cardiovascular risk factors 
including hypertension are reported to be growing up among individuals living with 
HIV/AIDS (Nsagha et al., 2015). 
Besides the traditional risk factors, hypertension in HIV patients can be linked to, 
inflammations and immune response (Madhur et al., 2016). However, it’s unclear whether 
traditional risk factors may interact with additional factors in HIV patients to increase the risk 
of hypertension. Therefore, there is a need to explore more on the prevalence of hypertension 
and the way it can be influenced by HIV related factors. 
1.3 Rationale of the study 
The hypertension is a unique challenge to the health system including to the treating 
physician. Although there are previous studies that have been undertaken to explore 
hypertension and associated factors in HIV patients, however, the true cause of hypertension 
in HIV patients remains unclear. Furthermore, a small number of studies have been 
undertaken in Tanzania to find out the prevalence of hypertension and associated factors. 
Therefore data from this study will support the improvement of quality health care among 
HIV/AIDS patients, particularly in the screening, prevention, management and control of 
hypertension. Furthermore, it will inform decision-makers and key stakeholders for the better 
allocation of resources concerning hypertension in HIV/AIDS patients. 
1.4 Objectives 
1.4.1 General objective 
The broad objective of the study was to determine the prevalence of hypertension and its 
association with selected HIV related factors in HIV infected adults on ART in the 
Bagamoyo district council.  
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1.4.2 Specific objectives 
(i) To achieve the above broad objective, the study has the list of specific objectives 
mention below: 
(ii) To determine the prevalence of hypertension in HIV infected adults on ART attended 
the selected care and Treatment Clinics (CTCs) of the Bagamoyo district council. 
(iii) To assess selected HIV related factors contributing to hypertension in HIV infected 
adults on ART attended the selected care and Treatment Clinics (CTCs) of the 
Bagamoyo district council. 
1.5  Research questions 
(i) Is the prevalence of hypertension among HIV patients higher among females than in 
the male? 
(ii) Is there an association between HIV related factors and hypertension among HIV 
patients who are on ART? 
1.6 Research hypothesis 
(i) Prevalence of hypertension among HIV patients is higher among females than in the 
male. 
(ii) There is an association between HIV related factors and hypertension among HIV 
patients who are on ART. 
1.7 Significance of the study 
The study has provided data that can inform the integrated approaches of HIV and 
hypertension as well as other issues that might affect the health and wellbeing of HIV 
infected persons at care and treatment clinics (CTCs). The findings of the study are going to 
inform the formulation of strategies and interventions for efficient prevention and 
management of hypertension among individuals suffering from. 
Also, the study contributes to the knowledge of the magnitude of hypertension and its 
association with HIV related factors in Bagamoyo district, eastern Tanzania and outlines a 




1.8 Delineanation of the study 
Hypertension in HIV/AIDS context is a very relevant public health problem. Risk factors for 
hypertension among HIV patients can be either traditional or non-traditional risks. Traditional 
risks are established risks include age, obesity, and smoking. However, it’s unknown if 
traditional risk factors may interact with HIV related factors to increase the risk of 
hypertension. 
There is previous studies which have investigated the prevalence of hypertension and 
associated factors. The scope of this dissertation is to provide the information regarding the 
prevalence of hypertension and its association to HIV related factors in Bagamoyo districts, a 





2.1 General information about hypertension and HIV 
Hypertension is the leading cause of premature deaths and disability worldwide (Forouzanfar 
et al., 2015). In the years 2010, it was estimated that about 1.3 billion adults were 
hypertensive worldwide  (Bloch, 2016).  In Tanzania, the magnitude of hypertension in the 
community has been approximated to range between 16% and 22% (Kavishe et al., 2015). 
Hypertension has also been reported as a leading cause of deaths related to stroke and heart 
failure among hospitalized patients in Tanzania (Peck  et al., 2013). 
About HIV/AIDS, in the year 2018, it was reported that 37.9 million people were living with 
HIV/AIDS and 20.9 million among them were on ART, globally (UNAIDS, 2019). 
According to the Unaids, in the year 2017, 1.5 million people were living with HIV/AIDS 
and 65 000 had new HIV infections in Tanzania (UNAIDS, 2018). 
2.2 Background information about hypertension in HIV patients 
Effective use of antiretroviral therapy (ART), has greatly upgraded the quality of life and 
survival of individuals suffering from HIV/AIDS (Chastain et al., 2015). However, the 
incidence, prevalence rate and mortality from cardiovascular risk factors including 
hypertension are reported to be growing up (Furrer et al., 2017; Nduka et al., 2016). For 
instance, in a  meta-analysis of HIV patients, the prevalence of hypertension was 34.7% in 
the HIV infected individuals on ART in comparison to 12.7% in those who were not in the 
use of ART  (Xu et al., 2017). In Tanzania, the hypertension prevalence rate of 28.3%  has 
been reported in HIV patients on ART and this was higher compared to the prevalence of 
5.3% in HIV ART-naïve and 16.3% in those without HIV infection (Peck et al., 2014).  
Besides the traditional risk factors, hypertension in HIV patients can be linked to, 
inflammations and immune reactions (Madhur et al., 2016). Traditional risks include risks 
such as increasing age, sex and increasing body mass index (Riaz et al., 2016). However, it’s 
unclear whether traditional risk factors may interact with additional factors in HIV patients to 
increase the risk of hypertension. Therefore, it’s important to investigate if selected HIV-
related factors influence the risk of hypertension in individuals living with HIV/AIDS. 
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2.3 Pathophysiology of hypertension in HIV patients 
The mechanism of hypertension in HIV/AIDS patients is complex (Calisman, 2017). The key 
steps in the mechanism of hypertension in HIV patients have been summarized in Fig.1. 
Factors that may contribute to the pathogenesis of hypertension in HIV patients include 
aging, obesity, dyslipidemia, insulin resistance, ART toxicity, viral chronic inflammation, 
and immune activation (Calisman, 2017). 
 
Figure 1: Diagram of the mechanism of hypertension in HIV positive patients  
               (Fahme, Bloomfield & Peck 2016) 
Key: 
ART = antiretroviral therapy;  CD163 = cluster of differentiation 163 protein,  CD4 = cluster 
of differentiation 4, CMV = cytomegalovirus, GALT = gut-associated lymphoid tissue, IL-6 
= interleukin-6, LPS = lipopolysaccharide, RAAS = renin-angiotensin-aldosterone system 
and sCD14 = soluble cluster of differentiation 14 protein. 
2.4 Hypertension and antiretroviral therapy in HIV patients 
Use of antiretroviral therapy has been attributed to the pathophysiology of hypertension 
perhaps through drug toxicity, lipodystrophy, inflammation and immune response (Villa et 
al., 2018; Madhur et al., 2016). For instance, tenofovir a non-protease inhibitor can cause 
hypertension due to its ability to cause renal failure, leading to secondary hypertension 
(Ojehet al., 2018).  
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Protease inhibitors such as atazanavir and lopinavir can contribute to hypertension through 
dyslipidemia, lipodystrophy, and atherosclerosis (Zhou, Pandak, Lyall, Natarajan & 
Hylemon, 2005). An observational study  indicated that both lipoatrophy and lipohypertrophy 
significantly associated with elevation of blood pressure in HIV patients (Crane, 2010). 
Despite that, there is a variation of results from past studies that have analyzed the association 
between ART exposure and hypertension in HIV patients. For example, one cross-sectional 
study indicated a lack of an association between the tenofovir-based regime and hypertension   
(Medina-torne et al., 2012), contrary to a prospective cohort that found a significant and 
positive association between tenofovir-based regime and hypertension (Crane, Rompaey & 
Kitahata, 2006). Regarding ART classes, a cross-sectional study from Uganda conducted in 
2017, found that non-protease inhibitors users had a double risk of hypertension compared to 
the individual who was not using non-protease inhibitors (Munderi, 2017). 
Protease inhibitors were reported to be associated with hypertension in HIV patients (Fahme, 
Bloomfield & Peck, 2016). The mechanism by which PIs may contribute to hypertension in 
HIV patients includes lipodystrophy, dyslipidemia, and atherosclerosis (Dressman et al., 
2003).  Furthermore, Protease inhibitors have been implicated to cause hypertension through 
the renin-angiotensin-aldosterone system (RAAS) activation (Boccara et al., 2010). The 
possible mechanism is that PIs may activate the adipokine-mediated route which may cause 
the operation of the adipose RAAS (Boccara et al., 2010). The activation of RAAS in turn 
can cause salt/ water retention and a rise in blood pressure. 
Despite that, there are inconsistencies in the results of the association between PIs and 
hypertension from previous studies. For instance,  a cohort study conducted in the USA 
reported that prior exposure to lopinavir/ritonavir had an association with elevated blood 
pressure (Crane, Rompaey & Kitahata, 2006). However, in a cross-sectional study by 
Medina-Torne et al. (2012), lopinavir/ritonavir was not significantly associated with elevated 
blood pressure  (Medina-Torne et al., 2012). 
2.5 Hypertension and the immune system in HIV patients 
Hypertension has been also reported to associate with the immune system in HIV patients  
(Peck et al., 2014). Though the precise mechanism is not well understood, the proposed 
mechanism may involve persisting immune response, including an elevated level of CD4+ T 
cell and CD+8 T cell (Brites-alves et al., 2018; Calisman, 2017). For example, following 
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initiation of ART, there is an initial drop of the CD4+T cell followed by a rapid recovery of 
the immune system, a process known as immune reconstitution inflammatory syndrome 
(IRIS). According to previous studies, lower nadir CD4+ cell counts (the lowest CD4  count 
of an individual ever recorded)  have been linked to a higher incidence of hypertension 
among HIV patients who are on ART  (Peck et al., 2014; Manner et al., 2013). 
Also, the immune mechanism has been involved in the mechanism of hypertension in HIV 
patients through microbial translocation. HIV can infect CD4+T the gut-associated lymphoid 
tissues weakening and destroying the integrity of the natural immune system in the gut 
mucosa  (Blodget et al., 2012; Chun et al., 2008). This facilitates the pathogens to enter into 
systemic blood circulation causing an elevation of lipopolysaccharides a marker of microbial 
translocation (Kelesidis et al., 2012; Jiang et al., 2009). A high level of lipopolysaccharides 
may cause hypertension through several mechanisms. According to previous studies 
conducted in mice, lipopolysaccharides has been shown to stimulate the production of 
Prostaglandin E2, angiotension11, RAAS activation, and trigger of the sympathetic nervous 
system which can end up to hypertension (Lund, Brooks, Faraci & Heistad, 2019).   
Association between CD4+T cell count and hypertension in HIV patients has been 
investigated in HIV patients (Peck et al., 2014; Medina-torne et al., 2012). However, there is 
a variation in the results from previous studies regarding the association between CD4+T cell 
count and hypertension. For example, an observational study conducted in America reported 
a lack of an association between hypertension and recent CD4+cell count (Medina-Torne et 
al., 2012).  While, an observational study from north-western Tanzania has indicated a 
positive association between Hypertension and higher current CD4+ cell count (Peck et al., 
2014). Generally, there is inconsistency in results from previous studies regarding the 
association between CD4+cell count and Hypertension. 
2.6 Hypertension and tuberculosis in HIV patients 
There has been some evidence that TB may increase cardiovascular risk including 
hypertension risk through inflammatory and autoimmune processes (Calisman, 2017; 
Borchsenius, Rudolf & Wejse, 2017). It has been postulated that immune activation and 
cytokine production during inflammatory reactions tend to speed up the atherosclerosis 
process which can cause hypertension (Rajendran et al., 2013). Furthermore, TB has been 
associated with  hypertension, because it can lead to the diabetes mellitus  (Ogbera et al., 
2015), and diabetes mellitus itself is the potential predictor of the overall cardiovascular risk 
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including hypertension (Petrie et al., 2018). Additionally, hypertension may occur 
secondarily from renal failure after TB causing extensive destruction of kidney parenchyma 
tissues  (Shen et al., 2015).  
Even though TB is the most prevalent and severe co-infection in HIV patients (Calisman, 
2017; Fatou et al., 2017), there has been relatively little research into how TB infection 
influences hypertension in HIV patients in sub-Sahara Africa. In Tanzania, Njelekela et al. 
(2016), reported that no significant association between current TB/HIV co-infection and 
hypertension in adults HIV naïve patients (Njelekela et al., 2016). Although the same study 
by Njelekela et al. (2016), reported that a prior history of TB tends to decreases the risk of 
hypertension in adults HIV naïve patients (Njelekela et al., 2016). 
From the literature, much of what has been pinpointed regarding the influences of TB on 
hypertension comes from studies that were conducted in the general population in developed 
countries. A little has been done to investigate the association between TB and hypertension 




MATERIALS AND METHODS 
3.1 Study design and location 
The design of the study was cross-sectional involving HIV patients who were on ART 
conducted between March and May 2019, in Bagamoyo district, eastern Tanzania. The 
district is located in the coastal region which has an HIV prevalence rate of 6.4% (Ministry of 
Health, 2016). Data were collected from 2 public clinics (Bagamoyo district hospital and 
Kerege health center) which were purposively selected based on their relatively large size and 
presence of established patient’s record database (computer-based record system). The two 
clinics provide care and treatments based on the national HIV/AIDS guidelines of Tanzania 
(Ministry of Health, 2017). 
3.2 Inclusion and exclusion criteria 
The inclusion criteria were being HIV positive, aged above 18, on ART, who gave consent 
for participation. Women who reported to be pregnant and those on contraceptive pills were 
excluded.  
3.3 Sample size estimates 
To calculate the sample size the formula below was used:  
  N=P (1-P) (Z/E)  
Whereby margin of error (E) = 5%, P=Prevalence 
N=estimated required sample size, Z= 95% confidence interval = 1.96, attrition of 10% for 
missing data. Pravelence (P) 26.2% from a study by Kagaruki et al. 2014 
0.262(1-0.262) (1.96/0.05)2, margin of error (E) = 5%, P=Prevalence 





3.4 Blood pressure measurement and definition 
Blood pressure was measured as per required standards in the right arm, utilizing a mercury 
sphygmomanometer of appropriate size, with individual participants in sitting in a relaxed 
position and upright position (Joint National Committee, 2004).  Two readings were taken 10 
minutes apart and an average of two results was turned to account in the final analysis. 
Hypertension was defined as systolic blood pressure (SBP) of  ≥ 140 mmHg, diastolic blood 
pressure (DBP) of ≥ 90 mmHg  (Joint National Committee, 2004) or taking ant-hypertensive 
medications regardless of the blood pressure value measured on the day of data collection. 
3.5 Anthropometric measurement 
Bodyweight (precision of 0.1 kg) was weighed using the patients weighing machine (seca 
scale) with individual participants at minimal clothes and wearing no shoes. Body height was 
assessed using a stadiometer (precision of 0.1 cm) participant wearing no shoes. Body mass 
index (BMI) was computed utilizing the formula: weight in kilogram (kg) divided by the 
square of height in meters (Kg/m2). BMI was classified and defined using the WHO protocol 
as follows; underweight  < 18.5 kg/m2, normal body weight 18.5—24.9 kg/m2, overweight  
25—29.9 kg/m2, and obese   ≥  30 kg/m2 (World Health Organization, 2004). 
3.6 Sociodemographic, HIV related factors collection and definition 
The structured questionnaire administered by trained health care workers was used to collect 
the sociodemographic, family history of hypertension, current history of TB and history of 
TB in the past 5 years. 
In addition to the individual interview, the following information was extracted directly from 
patient record card or computerized patients’ database system: duration since HIV diagnosed, 
recent CD4+cell count, the current class of ART, and individual cART. 
Duration since HIV diagnosis was defined as the time in years at which HIV diagnosis was 
confirmed as it was documented in patient record cards.  Recent CD4+cell count was defined 
as the CD4+T cell count measured in the past 6 months. Current TB was defined as currently 
being on anti-TB medication after sputum analysis or chest radiography. History of TB in the 




3.7 Exposure, outcome and confounding Variables 
The primary outcome variable of interest was hypertension defined as blood pressure ≥ 
140/90 mmHg, or being on medications for hypertension. Exposure variables of interest in 
the study were: duration since HIV diagnosis, recent CD4+cell count, the current class of 
ART, individual cART, current TB/HIV co-infection, and history of TB in the past 5 years. 
The potential confounders included during the analysis were: age, sex, obesity, and family 
history of hypertension. 
3.8 Data management and analysis 
Data was gathered by a means of a structured questionnaire and then entered into an Excel 
sheet. Before data was entered in the Excel sheet, a completed questionnaire was reviewed 
for completeness and clarity. Before data analysis, another review was done for errors, 
missing data, and inconsistencies. The analysis was done using STATA version 13. We 
included 328 participants in the final analysis and 33 participants had missing data regarding 
the recent CD4+cell count. In 33 participants with missed data on CD4+cell count, they had 
CD4+cell count either not taken at all or taken in a period of more than 6 months. A 
descriptive analysis (percentage) was used to summarize the data.  
Logistic regression was executed to check for an association between HIV related factors and 
hypertension. In the multivariate analysis, we included factors from univariate analysis with 
p-value ≤ 0.005 include age, body mass index, and family history of hypertension. Sex and 
current class of ART were included as a forced variable during multivariate analysis. 
However, ART as the class was not adjusted together with the individual combination of 
ART during multivariate analysis because of co-linearity. In multivariate analysis variables 
were added by a forward selection technique with the variables of greater theoretical 
significance entered first. 
3.9 Ethical approval 
The protocol of the study was reviewed and certified by the research ethics committee of the 
Ifakara Health Institute, Bagamoyo district executive director office as well as the authority 
of the respective health facility. Written informed consent was attained from each of the 




RESULTS AND DISCUSSION 
4.1 Results 
4.1.1 Sociodemographic factors and clinical profile of the participants 
A total of 328 study participants were included in the analysis. Out of 328 participants, 212 
(64.6%) were females and 116 (35.4%) male (Table 1). In the descriptive analysis of the age 
in years, 132 (40.24%), 151 (46.06%) and 45 (13.72%) were individuals aged 18-39 years, 
40-59 years, and ≥ 60 years, respectively (Fig. 2). Out of 328 participants, 213 (64.9%) were 
peasants and 115 (35.06%) non-peasants (Table 1). 
In further analysis out of 328 participants, 89 (25%) were either obese or overweight, and 161 
(49%) of the participants diagnosed with HIV within the last 5 years (Table 1). Current 
alcohol drinker and cigarette smokers were observed in 42 (12.8%) and 17 (5.18%) 
respectively (Table 1). 
 



























Table 1: Socio demographic and clinical profile of the participants 
Factors of interest   n (%) 
Age (Years)  
18-39 132 (40.24) 
40-59 151 (46.06) 
≥ 60 45 (13.72) 
  
Sex  
Female  212 (64.63) 
Male  116 (35.37) 
  
Occupation   
Peasants 213 (64.94) 
Others  115 (35.06) 
  
Alcohol drinker  42 (12.80) 
  
Current cigarette smokers 17 (5.18) 
  
BMI (kg/m2  )  
Underweight (<18.5) 46 (14.02) 
Normal weight(18.5—24.9) 193 (58.84) 
Overweight (25—29.9) 51 (15.55) 
Obese (≥ 30) 38 (11.59) 
  
Family history of hypertension 41 (12.50) 
Overall  328 
 
The HIV related factors characteristics of the participants were as follows; Out of 328 
participants, 161 (49.09%), 110 (33.54%) and 57 (17.38%) had duration since HIV diagnosis 
of < 5 years, 5-9 years and ≥ 10 years respectively (Table 2). There were 304 (92.68%) 
patients on non-protease inhibitors and 24 (7.32%) on protease inhibitors as the class of ART 
(Table 2). The majority of patients 285 (86.89%) were on tenofovir based cART and the rest 
had been either on zidovudine or atazanavir (Table 2). Regarding the TB status, out of 328 
participants, 2 (0.61%) patients had a current HIV/TB co-infected and 46 (14%) of patients 
had a history of TB in the past 5 years (Table 2). 
Data on the recently CD4+ cell was available in 25 (8.47%), 75 (25.42%), 75 (25.42%) and 
120 (40.68%) of the patients with CD4+ cell count of < 100, 100-349, 350-499 and ≥ 500 
respectively (Table 2). However, there were missed data for CD4+cell count in 33 
participants, which is equivalent to 10 percent of all the participants. Furthermore, out of 328, 
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2 (0.61%) patients had current HIV/TB co-infected and 46 (14%) of patients had a history of 
TB in the past 5 years (Table 2). 
Table 2: HIV related factors characteristics of the participants 
Factors of interest   n (%) 
Duration since HIV diagnosed (years)  
< 5 161 (49.09) 
 5—9  110 (33.54) 
 ≥ 10 57 (17.38) 
  
Recently CD4 +cell count(cell/µl)   
<100 25 (8.47) 
100- 349  75 (25.42) 
350—449  75 (25.42) 
 ≥ 500  120 (40.68) 
  
Current class of ART   
Protease inhibitors   24 (7.32) 
Non-protease inhibitors  304 (92.68) 
  
Individual cART  
Zidovudine  19 (5.79) 
Tenofovir  285 (86.89) 
Atazanavir 24 (7.32) 
  
History of TB   
Current TB/HIV co-infection 2 (0.61) 
History of TB in past 5 years 46 (14.02) 
Overall  328 
4.1.2 The prevalence of hypertension 
In the current study, the overall prevalence of hypertension in HIV patients on ART was 
29.3 % (Table 3). According to gender, the prevalence was 33 (28.5%) in males and 63 
(29.7%) in females (Table 3). The prevalence of hypertension was higher in the individuals 
aged ≥ 60 years 24 (53.3%), compared to 50 (33.1%) in the individuals aged 40-59 years, 
and 22 (16.7%) in the individuals aged 18-39 years (Table 3). Regarding the BMI, the 
prevalence of hypertension was 55.3%, 39.2%, 27.5% and 4.4% in obese, overweight, 
normal weight and underweight respectively (Table 3). 
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Table 3: Socio demographic characteristics associated with hypertension 








Age (Years)    
18-39 22 (16.7) 111 (83.3) 132 
40-59 50 (33.1) 101 (66.9) 151 
≥ 60 
 
24(53.3) 21 (46.7) 45 
Sex    
Female  63 (29.7) 149 (70.3) 212 
Male  
 
33(28.5) 83 (71.5) 116 
Occupation     
Peasants 63 (29.6) 150 (70.4) 213 
Others  
 
33 (28.7) 82 (71.3) 115 
 Alcohol drinker  13 (30.9) 29 (69.1) 42 
Smoking cigarette  7 (41.2) 10 (58.8) 17 
    
 BMI (kg/m
2
)    
Underweight (<18.5) 2 (4.4) 44 (95.6) 46 
Normal weight (18.5—24.9) 53 (27.5) 140 (72.5) 193 
Overweight (25—29.9) 20 (39.2) 31 (61.8) 51 
Obese (≥ 30) 
 











Overall  96 (29.3) 232 (70.7) 328 
BMI: Body mass index. 
Furthermore, during the descriptive analysis of HIV related factors, the prevalence of 
hypertension was 28%, 30.7%, 29.3% and 30.0% in the participants with the CD4+ cell 
counts of < 100, 100-349, 350-499 and ≥ 500 respectively (Table 4). Also, the prevalence of 
hypertension was 12.5% and 30.6% in the participants who were on protease inhibitors and 
non-protease inhibitors respectively (Table 4). The participants with current TB-HIV co-
infection had a prevalence of 50% and participants with a history of TB in the past 5 years 
had a prevalence of 32.6% (Table 4). 
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Table 4: HIV related factors associated with hypertension 









    
Duration since HIV diagnosed 
(years) 
   
< 5 48 (29.8) 113 (70.2) 161 
  5—9  33 (30.0) 77 (70.0) 110 
  ≥ 10 
 
15 (26.3) 42 (73.7) 57 
Recent CD4 +cell count(cell/µl)     
<100 7 (28) 18 (72) 25 
 100- 349  23 (30.7) 52 (69.3) 75 
 350—449  22 (29.3) 53 (70.7) 75 
 ≥ 500  
 
36 (30.0) 84 (70.0) 120 
Current class of ART     
Protease inhibitors   3 (12.5) 21 (87.5) 24 
Non- protease inhibitors  93 (30.6) 211 (69.4) 304 
    
Individual cART    
Zivodune 8 (42.1) 11 (57.9) 19 
Tenofovir  85 (29.4) 204 (70.6) 289 
Atazanavir   3 (12.5) 21 (87.50) 24 
    
History of TB      
Current TB/HIV co-infections 1 (50.0) 1 (50.0) 2 








Overall  96 (29.3) 232(70.7) 328 
 
cART = combination antiretroviral therapy, CD4 = cluster of differentiation 4, HIV = human 
immunodeficiency virus, and TB = tuberculosis. 
4.1.3 Univariate analysis 
In the univariate logistic regression analysis, the sociodemographic factors that significantly 
associated with increased odds of having hypertension were: increasing age, higher BMI, 
and family history of hypertension. The odds for hypertension were highest among 
individuals aged ≥ 60 years 5.71 (2.72-12.01) < 0.001 and the age group 40-59 years had an 
odds ratio of 2.48 (1.40-4.37) < 0.005 (Table 5). 
Regarding body mass index, Obese hold highest odds ratio of 3.3 (1.60-6.66) < 0.001, 
followed by overweight 1.70 (0.89-3.25) 0.105 (Table 5). Also, family history of 
hypertension was significantly associated with increasing odds of having hypertension 
having an odds ratio of 2.64 (1.36-5.15) 0.004 (Table 5). Both of sex (female) 1.06 (0.65-
1.78) 0.809, occupation (non-peasant) 0.96 (0.58-1.58) 0.867, current alcohol drinker 1.10 
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(0.54-2.21) 0.80 and current cigarette smokers 1.75 (0.64-4.73) 0.273 were not significantly 
associated with hypertension (Table 5). 
Table 5: Univariate analysis of sociodemographic associated with hypertension (N=328) 
Factor of interest  n Odds ratios (95% CI) P value 
Age (years)     
18-39 132 1  
40-59 151 2.48 (1.40-4.37) 0.002 
≥  60 45 5.71 (2.72-12.01) 0.001 
    
Sex     
Male  116 1  
Female  212 1.06 (0.65-1.78) 0.809 
    
Occupation status     
Peasant  213 1  
Non peasant  115 0.96 (0.58-1.58) 0.867 
    
 Alcohol drinker     
                              No 286 1  
                              Yes 42 1.10 (0.54-2.21) 0.797 
    
Smoking cigarette    
                               No 311 1  
                               Yes 17 1.75 (0.64-4.73 0.273 
    
BMI (kg/m2  )    
Normal weight(18.5—24.9) 193 1  
Underweight (<18.5) 46 0.12 (0.28-0.51) 0.004 
Overweight (25—29.9) 51 1.70 (0.89-3.25) 0.105 
Obese (≥ 30 ) 38 3.3 (1.6-6.66) 0.001 
Family history of hypertension    
                                                    No 287 1  
                                                   Yes 41 2.64 (1.36-5.15) 0.004 
BMI:  Body mass index  
About HIV related factors, univariate analysis revealed that the only factor significantly 
associated with increased odds of hypertension was zidovudine 5.09 (0.86-10.24) 0.04 
(Table 6). Both of duration since HIV diagnosis, CD4+cell count, tenofovir, current TB/ 
HIV co-infection, and history of TB in the past 5 years were not significantly associated 




Table 6: Univariate analysis of HIV related factors 
Factor of interest  
Duration since HIV diagnosed (years) 
n Odds ratios (95% CI) P value 
< 5 161 1  
5—9  110 1.01 (0.59-1.71) 0.974 
 ≥ 10 57 0.84 (0.42-1.66) 0.617 
    
Recent CD4 + cell count(cell/µl)     
<100 25 1  
100-349 75 1.13 (0.42-3.09) 0.801 
350—499 75 1.07 (0.39-2.91) 0.899 
≥ 500 120 1.10 (0.42-2.87) 0.842 
    
Current class of ART     
Protease inhibitors   24 1  
Non-protease inhibitors  304 3.09 (0.89-10.6) 0.074 
    
Individual cART    
Zidovudine 19 5.09 (1.12-23.14) 0.493 
Tenofovir  289 2.98 (0.86-10.24) 0.001 
Atazanavir  20 Omitted  
    
History of TB     
Current TB/HIV co-infections    
                                                     No 326 1  
                                                     Yes  2 2.42 (0.15-39.28) 0.531 
History of TB in past 5 years      
                                                     No 282 1 0.595 
                                                     Yes        46 1.2 (0.62-2.34) 0.592 
cART = combination antiretroviral therapy, CD4 = cluster of differentiation 4, HIV= human 
immunodeficiency virus and TB = tuberculosis. 
4.1.4 Multivariate analysis 
In multivariate analysis, the sociodemographic characteristics that associated with increased 
odds of hypertension were age group of 40-59 years, 3.40 (1.80-6.41) 0.001, ≥ 60 years, 9.25 
(3.96-21.60) 0.001, current smokers 2.12 (0.65-6.90) 0.214 (Table 7), obesity 3.63 (1.60-
8.26) 0.002, and family history of hypertension 2.73 (1.27-5.84) < 0.009 (Table 7). 
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Table 7: Multivariate analysis sociodemographic associated with hypertension (N=328) 
Factor of interest    n Odds ratios (95% CI) P value  
Age (years)     
18-39 132 1  
40-59 151 3.40 (1.80-6.41) 0.000 
≥ 60  45 9.25 (3.96-21.60) 0.000 
    
Sex     
Male  116 1  
Female  212 0.78 (0.43-1.40) 0.402 
    
Occupation status     
Peasant  213 1  
Non-peasant  115  1.24 (0.69-2.24) 0.472 
    
Current social behaviour     
Alcohol drinker     
                              No 286 1  
                              Yes  42 1.09 (0.54-2.21 0.797 
    
   Smoking cigarette    
                               No 311 1  
                              Yes  17 1.29 (0.57-2.92) 0.214 
    
BMI (kg/m
2
)    
Normal weight (18.5—24.9) 193 1  
Underweight (<18.5)  46 0.70 (0.02-0.32) 0.001 
Overweight (25—29.9) 51 1.61 (0.77-3.36) 0.201 
Obese (≥ 30)  
 
Family history of hypertension 
                                                   No   

















In further multivariate analysis, HIV related factors that were independently associate with 
increased odds of hypertension were, non-protease inhibitors 4.31 (1.16-16.03) 0.029, and 
tenofovir 4.27 (1.15-15.96) 0.031 (Table 8). However, the duration since HIV diagnosis, 
recent CD4+count, zidovudine, current TB/HIV co-infection and history of TB in the past 5 
years were not found to have statistical significance with hypertension in multivariate 
analysis (Table 8). 
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Table 8: Multivariate analysis HIV related factors associated with hypertension (N=328) 
Factor of interest    n Odds ratios (95% CI) P value  
Duration since HIV diagnosed (years)    
< 5 161 1  
5—9  110 0.82 (0.44-1.51) 0.521 
 ≥ 10 57 0.61 (0.27-1.35) 0.222 
    
Recent CD4 + cell count(cell/µl) 
c  
    
<100 25 1  
100-349 75 0.90 (0.30-2.70) 0.845 
350—499 75 1.04 (0.34-3.16) 0.940 
≥ 500 120 1.25 (0.43-3.60) 0.677 
    
Current class of ART    
Protease inhibitors   24 1  
Non -protease inhibitors  304 4.31 (1.16-16.03) 0.029 
    
    
Individual cART    
Zidovudine 19 4.66 (0.91-23.99) 0.065 
Tenofovir  285 4.27 (1.15-15.96) 0.031 
 Atazanavir  24 Omitted  
    
Current TB/HIV co-infections    
                                                     No 326 1  
                                                     Yes   2  3.13 (0.12-80.41) 0.491 
    
History of TB in past 5 years      
                                                     No 282 1  
                                                     Yes         46  1.15 (0.55-2.43) 0.711 
cART= combination antiretroviral therapy, CD4= cluster of differentiation 4, HIV= human 










4.2 Discussion of the results 
The study found the prevalence of hypertension among HIV patients on ART to be 29.3%%. 
The odds of having hypertension were significantly and positively associated with 
increasing age, obesity, and family history of hypertension, non-protease inhibitors, and 
tenofovir. Both of duration since HIV diagnosis, recently CD4+cell count, zidovudine and 
history of the TB infection in the last past 5 years were found not significantly associated 
with increased odds of hypertension. The high prevalence (29.3%) in the study, is similar to 
the observed prevalence in previous studies in HIV patients on ART (Xu et al., 2017; Peck 
et al., 2014). The result together with those from previous studies strengthens the evidence 
that the prevalence of hypertension is greater among individuals living with HIV/AIDS on 
ART. 
The observed significant and positive association between socio-demographic(increasing 
age, and obesity) is concordant with preceding studies (Furrer et al., 2017; Fatou et al., 
2017). The findings support the evidence that traditional risk factors are potential predictors 
of hypertension even in HIV patients. 
About HIV related factors, duration since HIV diagnosis was found not associated with 
increasing odds of having hypertension, similar to what has been reported in a previous 
prospective observation cohort (Krauskopf et al., 2013). However, the result differs from 
what was reported by Medina-Torne et al. (2012). According to the analyzed data by 
Medina-Torne et al. (2012) there was a positive and significant association between the 
duration of HIV infection and hypertension (Medina-torne et al., 2012). The difference 
might be explained by the way duration of HIV was defined in the two settings. In the study 
by Medina-Torne et al. (2012), the duration of HIV was defined as the mid-point between 
the first HIV positive test and the last negative test to the time of data collection (Medina-
torne et al., 2012). While the definition used in the current study was the time difference 
from the first seropositive and the time of study initiation. 
The study also investigated whether there is an association between ART and hypertension. 
There are prior studies that have explored the association between ART and hypertension in 
HIV patients (Munderi, 2017; Medina-Torne et al., 2012). The current study found that non-
protease inhibitors as the class of ART were significant and positively associated with 
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hypertension, similar to what has been communicated in an observational study conducted in 
Uganda (Munderi, 2017).   
In further analysis of the individual ART combination therapy, tenofovir was significantly 
and positively associated with increased odds of having hypertension, similar to what has 
been reported in a previous study (Villa et al., 2018). Tenofovir has been implicated to cause 
hypertension due to its kidney toxicity (Ru et al., 2018). However, the current study didn’t 
measure the serum level of tenofovir to check for the tenofovir toxicity, therefore the study 
cannot conclude whether observed hypertension was directly linked to tenofovir toxicity. 
Furthermore, zidovudine based ART was found associated with increased odds of having 
hypertension in the multivariate analysis though the association was not statistically 
significant, contrary to the findings in research conducted in North America which indicated 
a lack of significant association (Medina-Torne et al., 2012). The contrasting results 
possibly are due to the dissimilarity in ethnicity, socio-demographic profiles and study 
design between two studies. 
The study also investigated the influences of the immune response on hypertension in HIV 
patients who were on ART. There was no significant association between recent CD4+cell 
count and hypertension, similar to results reported from previous studies (Furrer et al., 2017; 
Dimala et al., 2016; Medina-torne et al., 2012). However, the result from the current study 
differs from what has been reported in a previous study in north-western Tanzania which 
reported a positive association between hypertension and a high CD4+cellcount (Peck et al., 
2014). The difference might be explained by the inclusion criteria and definition for 
CD4+cell count used in the two studies. According to Peck et al. (2014), the inclusion 
criteria were being an HIV patient on ART for at least 2 years, contrary to the current study 
which had no time limit when ART was initiated. Also, in the study by Peck et al. (2014) the 
blood sample for CD4+cell count, was taken on the same day as the measurement of first BP 
(Peck et al., 2014).  But, in the current study, CD4+cell count was obtained from patient’s 
records with a focus to the CD+ cell count which was taken and measured in a period of not 
more than the past 6 months counting from the day of recruitment. 
The study also investigated whether there is an association between TB and hypertension in 
adult HIV patients on ART. The interaction between TB infection and hypertension in HIV 
patients has been reported in the literature (Calisman, 2017). The possible mechanism by 
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which TB can cause hypertension is through the inflammatory process which can cause 
atherosclerosis (a risk factor for hypertension) (Calisman, 2017).  The current study found 
that current TB/HIV co-infection increases the odds of having hypertension 3.13 (0.12-
80.41) 0.491, though the association was not statistically significance. The result differs 
from the study by Njelekela et al. (2016) which indicates a lack of association between 
current TB/HIV co-infection and hypertension (Njelekela et al., 2016). However, the result 
from the current study should be interpreted with caution because of a small proportional 
(0.61%) of patients with current TB/HIV co-infection which was included in the final 
analysis. The association between current TB and hypertension cannot be justified based on 
only 2 patients with current TB infection which is a very small number to conclude. 
Therefore, the interpretation in the current study concerning the association between current 
TB/HIV co-infection and hypertension in HIV patients on ART should be made with 
caution. 
Finally, the study established that  history of TB in the past 5 years was associated with 
increased odds of having hypertension though the association was not statistically 
significance, contrary to a study by Njelekela et al. (2016). In a cross-sectional study by 
Njelekela et al. (2016) conducted in Dar es Salaam, Tanzania reported a protective effect of 
a prior history of TB against hypertension (Njelekela et al., 2016). However, there are 
differences to explain between the two studies. The current study had limit the history of the 
previous TB to a period of within the past 5 years whereas in the investigation by Njelekela 
et al. (2016), it had no time limit regarding the prior history of TB. Also, the current study 
recruited HIV patients who were on ART whereas Njelekela et al. (2016) recruited HIV-
ART naïve patients. Furthermore, the current study included potential confounders of 










CONCLUSION AND RECOMMENDATIONS 
5.1  Conclusion 
In conclusion, the current study established that the prevalence of hypertension in adults 
HIV patients on ART was high (29.3%) and was similar between female and male. The 
hypertension was significantly and positively associated with medications belong to the non-
protease inhibitors namely zidovudine and tenofovir based combinations therapy even after 
adjusting for other covariates. Both of the duration since HIV diagnosed, recent CD4+cell 
count and history of TB in the past 5 years were not associated with increased odds of 
having hypertension. 
5.2  Recommendations 
Derived from the outcome of the study, the following are the recommendations;  
(i) Routine screening and monitoring of blood pressure in HIV patients is required when 
attending HIV outpatient clinics. 
(ii) There should be the inclusion of lifestyle modification awareness programs into 
existing outpatient HIV clinics in Tanzania. 
(iii) Future prospective studies are recommended to investigate the incidence of 
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Appendix 1: Questionnaire 
1. Sex (circle only one) 
          1. Male      2. Female 
 
2. Age of participant……… (Completed years). 
 
3. What is your occupation? (Circle only one ) 
          1.  Peasant   2.Employed     3.Business     4.Unemployed      5.Others 
 
4. Do you currently drink alcohol? (circle only one)  
           1. Yes      2.No  
 
4.1      If Yes above, how many bottles on average do you drink per week?  
          1. (1-2)     2. (3--7)          3. (>7) 
5. Do you currently use any of the following tobacco products?  
            1. Smokes cigars    2. Tobacco pipes               3.None 
 
6. Is there a family history of hypertension?(circle only one) 
           1. Yes                   2.No 
 
B Blood pressure and anthropometric measurements 
 












S y s t o l i c … D i a s t o l i c …   
 
8. Body mass index  
           Bodyweight in kg (shoes removed)…………. 
           Height in meter................... 
           Body mass index (Weight (kg)/m2)……… 




9. Are you currently taking ant-hypertensive medication? 
1. Yes                       2. No 
 
 
10. Are you currently taking medications for diabetes? 
1. Yes                        2. No 
 
 
              HIV Related factors 
 
11. How long since your were diagnosed with HIV  
1. <5,                         2.5 -- 9                      3. ≥   10 
 
 
12. What is the CD4 COUNT? (taking within the last 6 months) 
Obtain the answer from patient card/CTC2. 
 
1. < 100                     2. 100---349               3. 350 ---4994.        4.   ≥ 500 
 
 
13. For how long since you started taking ARV medications? (months) 
Obtain the answer from patient card/CTC2. 
 
1. < 6                            2.6 --12                      3. > 12 
 
 
14. What ARV drug regime is currently taken by a participant? 
 Obtain the answer from patient card/CTC2. 
          1. Protease inhibitor      2. Non- protease inhibitors 
 
15. Which specific ARV regime a taken by a participant? 
(Obtain the answer from patient card/CTC2). 
1. Zidovudine based cART      2.Tenofovir based cART   3.Lopinavir     4.Atazanavir   
 
16. Are you current known to have tuberculosis or taking TB medication? (If yes check 
CTC2 card for verification and then go to question 17.0) if the answer is No go to 
question 18.0). 
     1. Yes but not on ant-TB medication     2. Yes, on ant-TB medication        3.No 
 
 
17. If yes in QN 16 above which types/form of tuberculosis is? (Check patient registry, TB 
treatment card or clinic database to confirm for the form of TB.) 





18. If no in QN 16 above have you ever suffered from TB in the past 5years? 
 
     1. Yes, and ant-TB drugs were taken          2.No     3. Can’t remember 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
